Combination therapy for platinum-resistant ovarian cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new combination of two drugs, RIF and Anlotinib, for people with ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must have ovarian, primary peritoneal, or fallopian tube cancer that has returned within 6 months of platinum chemotherapy.
- You must be able to take oral medications and have good organ function.
- You must not have had certain previous treatments or conditions like uncontrolled high blood pressure, blood clots, or other cancers recently.
- Women who could become pregnant must use effective birth control during and 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs for ovarian cancer that has come back quickly after platinum-based chemo. The goal is to see if adding an immunotherapy and a targeted pill to non-platinum chemo can help shrink tumors.
This trial tests a combination of three drugs (benmelstobart, anlotinib, and a low-dose chemo) for people with recurrent ovarian, fallopian tube, or primary peritoneal cancer. It aims to find a new option when standard platinum chemo no longer works or cannot be used.
This trial tests a combination of two drugs—Disitamab Vedotin and Anlotinib—for patients with ovarian cancer that has come back after platinum chemotherapy. It is designed for people whose tumors show a specific protein called HER2, and it aims to see if the combination is safe and effective.
This trial tests a new combination of drugs—QL1706 (which targets two immune checkpoints), nab-paclitaxel, and bevacizumab—for people with ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests a combination of a new immunotherapy drug (QL1706), chemotherapy, and a targeted therapy (anlotinib) for ovarian cancer that has come back after standard platinum treatment. The goal is to see if this triple therapy can shrink tumors or slow the cancer's return.
This trial tests a new drug, APG-2449, either alone or with another chemotherapy called PLD (pegylated liposomal doxorubicin). It is for people with advanced solid tumors, including ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if the drug can shrink tumors and how safe it is.
Hear when a new Platinum-resistant Ovarian Cancer (PROC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.